首页> BMC cancer> Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study.

Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study.

导出 OA

翻译打印收藏纠错

第一作者： Tomoyuki,Hayashi

第一单位： Department of Gastroenterology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-Machi, Kanazawa, Ishikawa, ZIP 920-8641, Japan.

作者： Tomoyuki,Hayashi ^[1] ; Taro,Yamashita ^[2] ; Takeshi,Terashima ^[1] ; Tsuyoshi,Suda ^[1] ; Hikari,Okada ^[1] ; Yoshiro,Asahina ^[1] ; Takehiro,Hayashi ^[1] ; Yasumasa,Hara ^[1] ; Kouki,Nio ^[1] ; Hajime,Sunagozaka ^[1] ; Hajime,Takatori ^[1] ; Kuniaki,Arai ^[1] ; Yoshio,Sakai ^[1] ; Tatsuya,Yamashita ^[1] ; Eishiro,Mizukoshi ^[1] ; Masao,Honda ^[1] ; Shuichi,Kaneko ^[1]

作者单位： Department of Gastroenterology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-Machi, Kanazawa, Ishikawa, ZIP 920-8641, Japan. ^[1] Department of Gastroenterology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-Machi, Kanazawa, Ishikawa, ZIP 920-8641, Japan. taroy@m-kanazawa.jp.;Department of General Medicine/Department of System Biology, Kanazawa University Hospital/Kanazawa University Graduate School of Medical Science, 13-1 Takara-Machi, Kanazawa, Ishikawa, ZIP 920-8641, Japan. taroy@m-kanazawa.jp. ^[2]

关键词 Chemokine Cytokine Growth factor Hepatic arterial infusion chemotherapy Hepatocellular carcinoma Sorafenib